Biosimilars for vasculitis: promise requires validation by quality studies

Saved in:
Bibliographic Details
Published in:Clinical rheumatology 2020-10, Vol.39 (10), p.3149-3151
Main Authors: Misra, Durga Prasanna, Patro, Pallavi, Agarwal, Vikas
Format: Article
Language:English
Subjects:
Biosimilar Pharmaceuticals
Drug Approval
Drug Industry
Granulomatosis with Polyangiitis
Humans
Letter to the Editor
Medicine
Medicine & Public Health
Rheumatology
Rituximab
Vasculitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c375t-4d8a65aa862e5474cf1b505605e0a4e7021ed76ac43f199e98fb4cfd2eda6ac13
cites cdi_FETCH-LOGICAL-c375t-4d8a65aa862e5474cf1b505605e0a4e7021ed76ac43f199e98fb4cfd2eda6ac13
container_end_page 3151
container_issue 10
container_start_page 3149
container_title Clinical rheumatology
container_volume 39
creator Misra, Durga Prasanna
Patro, Pallavi
Agarwal, Vikas
description
doi_str_mv 10.1007/s10067-020-05309-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2429770095</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2441910163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-4d8a65aa862e5474cf1b505605e0a4e7021ed76ac43f199e98fb4cfd2eda6ac13</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwAyxQJDZsAuNH4pgdVDxViQ2sLTeZIFdpQz0JUv8eQwpILNh4ZM-Z6zuXsWMO5xxAX1A8c52CgBQyCSYtdtiYK6lSY5TZZWPQGlLJTTFiB0QLABCF4ftsJIWWOld8zB6vfUt-6RsXKKnbkLw7KvvGd54uk7fQLj1hEnDd-4AUm42vXOfbVTLfJOs-XrtNQl1feaRDtle7hvBoWyfs5fbmeXqfzp7uHqZXs7SUOutSVRUuz5wrcoGZ0qqs-TyDLIcMwSnUIDhWOnelkjU3Bk1RzyNUCaxcfOVyws4G3Whv3SN1NpossWncCtuerFDCxMXBZBE9_YMu2j6sortIKW448FxGSgxUGVqigLV9C37pwsZysJ9J2yFpG5O2X0nbIg6dbKX7-RKrn5HvaCMgB4Bia_WK4ffvf2Q_ABW4iXc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2441910163</pqid></control><display><type>article</type><title>Biosimilars for vasculitis: promise requires validation by quality studies</title><source>Springer Link</source><creator>Misra, Durga Prasanna ; Patro, Pallavi ; Agarwal, Vikas</creator><creatorcontrib>Misra, Durga Prasanna ; Patro, Pallavi ; Agarwal, Vikas</creatorcontrib><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-020-05309-8</identifier><identifier>PMID: 32737641</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biosimilar Pharmaceuticals ; Drug Approval ; Drug Industry ; Granulomatosis with Polyangiitis ; Humans ; Letter to the Editor ; Medicine ; Medicine &amp; Public Health ; Rheumatology ; Rituximab ; Vasculitis</subject><ispartof>Clinical rheumatology, 2020-10, Vol.39 (10), p.3149-3151</ispartof><rights>International League of Associations for Rheumatology (ILAR) 2020</rights><rights>International League of Associations for Rheumatology (ILAR) 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-4d8a65aa862e5474cf1b505605e0a4e7021ed76ac43f199e98fb4cfd2eda6ac13</citedby><cites>FETCH-LOGICAL-c375t-4d8a65aa862e5474cf1b505605e0a4e7021ed76ac43f199e98fb4cfd2eda6ac13</cites><orcidid>0000-0002-5035-7396 ; 0000-0002-7645-5883 ; 0000-0002-4508-1233</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32737641$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Misra, Durga Prasanna</creatorcontrib><creatorcontrib>Patro, Pallavi</creatorcontrib><creatorcontrib>Agarwal, Vikas</creatorcontrib><title>Biosimilars for vasculitis: promise requires validation by quality studies</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><subject>Biosimilar Pharmaceuticals</subject><subject>Drug Approval</subject><subject>Drug Industry</subject><subject>Granulomatosis with Polyangiitis</subject><subject>Humans</subject><subject>Letter to the Editor</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Rheumatology</subject><subject>Rituximab</subject><subject>Vasculitis</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EoqXwAyxQJDZsAuNH4pgdVDxViQ2sLTeZIFdpQz0JUv8eQwpILNh4ZM-Z6zuXsWMO5xxAX1A8c52CgBQyCSYtdtiYK6lSY5TZZWPQGlLJTTFiB0QLABCF4ftsJIWWOld8zB6vfUt-6RsXKKnbkLw7KvvGd54uk7fQLj1hEnDd-4AUm42vXOfbVTLfJOs-XrtNQl1feaRDtle7hvBoWyfs5fbmeXqfzp7uHqZXs7SUOutSVRUuz5wrcoGZ0qqs-TyDLIcMwSnUIDhWOnelkjU3Bk1RzyNUCaxcfOVyws4G3Whv3SN1NpossWncCtuerFDCxMXBZBE9_YMu2j6sortIKW448FxGSgxUGVqigLV9C37pwsZysJ9J2yFpG5O2X0nbIg6dbKX7-RKrn5HvaCMgB4Bia_WK4ffvf2Q_ABW4iXc</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Misra, Durga Prasanna</creator><creator>Patro, Pallavi</creator><creator>Agarwal, Vikas</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5035-7396</orcidid><orcidid>https://orcid.org/0000-0002-7645-5883</orcidid><orcidid>https://orcid.org/0000-0002-4508-1233</orcidid></search><sort><creationdate>20201001</creationdate><title>Biosimilars for vasculitis: promise requires validation by quality studies</title><author>Misra, Durga Prasanna ; Patro, Pallavi ; Agarwal, Vikas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-4d8a65aa862e5474cf1b505605e0a4e7021ed76ac43f199e98fb4cfd2eda6ac13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biosimilar Pharmaceuticals</topic><topic>Drug Approval</topic><topic>Drug Industry</topic><topic>Granulomatosis with Polyangiitis</topic><topic>Humans</topic><topic>Letter to the Editor</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Rheumatology</topic><topic>Rituximab</topic><topic>Vasculitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Misra, Durga Prasanna</creatorcontrib><creatorcontrib>Patro, Pallavi</creatorcontrib><creatorcontrib>Agarwal, Vikas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Misra, Durga Prasanna</au><au>Patro, Pallavi</au><au>Agarwal, Vikas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biosimilars for vasculitis: promise requires validation by quality studies</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>39</volume><issue>10</issue><spage>3149</spage><epage>3151</epage><pages>3149-3151</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32737641</pmid><doi>10.1007/s10067-020-05309-8</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-5035-7396</orcidid><orcidid>https://orcid.org/0000-0002-7645-5883</orcidid><orcidid>https://orcid.org/0000-0002-4508-1233</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0770-3198
ispartof Clinical rheumatology, 2020-10, Vol.39 (10), p.3149-3151
issn 0770-3198
1434-9949
language eng
recordid cdi_proquest_miscellaneous_2429770095
source Springer Link
subjects Biosimilar Pharmaceuticals
Drug Approval
Drug Industry
Granulomatosis with Polyangiitis
Humans
Letter to the Editor
Medicine
Medicine & Public Health
Rheumatology
Rituximab
Vasculitis
title Biosimilars for vasculitis: promise requires validation by quality studies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T22%3A57%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biosimilars%20for%20vasculitis:%20promise%20requires%20validation%20by%20quality%20studies&rft.jtitle=Clinical%20rheumatology&rft.au=Misra,%20Durga%20Prasanna&rft.date=2020-10-01&rft.volume=39&rft.issue=10&rft.spage=3149&rft.epage=3151&rft.pages=3149-3151&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-020-05309-8&rft_dat=%3Cproquest_cross%3E2441910163%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-4d8a65aa862e5474cf1b505605e0a4e7021ed76ac43f199e98fb4cfd2eda6ac13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2441910163&rft_id=info:pmid/32737641&rfr_iscdi=true